INDEX
BIO-SCIENCE LAW REVIEW
VOLUME 15

CONTENTS
Subject Index i
Countries and Institutions ii
Contributors iii
Contributions iv
Case List iv

NAGOYA PROTOCOL
EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources (Article) 3 83
Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by Sophora Japonica (Article) 4 142

NANOMATERIALS
Regulation
Nanomaterials in the EU regulatory framework on chemical products (Article) 2 49

PATENTS
Competition
Gentech: the Court of Justice of the EU rejects a competition law defence in a patent royalty action (Case Comment) 4 165
Declaratory relief
Declaratory relief in the English Patents Court (Case Comment) 3 123
Diagnostic method
Diagnostic method claims in Canada (Article) 1 12
Experts
Experts in the Unified Patent Court (Article) 2 44
Patentability
Henry Carr jabs patentability in Men B case (Article) 4 131
Isolated nucleic acid sequences no longer patentable in Australia: D’Arcy v Myriad Genetics Inc (Case Comment) 1 25
Patentability of medical treatments (Article) 6 224
Pharmaceutical products
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119
Plant breeding
EU Commission notice on plants from essentially biological processes: problem solved? (Article) 6 231
Generating value in the soybean chain through royalty collection: an international study (Articles) 5 171
Plausibility
Blurred lines? Patents and plausibility (Article) 2 39
Public interest
Compulsory licences and patent revocations: does public interest rule the roost? (Article) 4 148

NAGOYA PROTOCOL
EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources (Article) 3 83
Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by Sophora Japonica (Article) 4 142

NANOMATERIALS
Regulation
Nanomaterials in the EU regulatory framework on chemical products (Article) 2 49

PATENTS
Competition
Gentech: the Court of Justice of the EU rejects a competition law defence in a patent royalty action (Case Comment) 4 165
Declaratory relief
Declaratory relief in the English Patents Court (Case Comment) 3 123
Diagnostic method
Diagnostic method claims in Canada (Article) 1 12
Experts
Experts in the Unified Patent Court (Article) 2 44
Patentability
Henry Carr jabs patentability in Men B case (Article) 4 131
Isolated nucleic acid sequences no longer patentable in Australia: D’Arcy v Myriad Genetics Inc (Case Comment) 1 25
Patentability of medical treatments (Article) 6 224
Pharmaceutical products
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119
Plant breeding
EU Commission notice on plants from essentially biological processes: problem solved? (Article) 6 231
Generating value in the soybean chain through royalty collection: an international study (Articles) 5 171
Plausibility
Blurred lines? Patents and plausibility (Article) 2 39
Public interest
Compulsory licences and patent revocations: does public interest rule the roost? (Article) 4 148

Supplementary Protection Certificates
Calculation of SPC duration: Case C–471/14 Seattle Genetics (Case Comment) 1 31
Latest case on SPCs: the CJEU rules in favour of chaos (Case Comment) 6 248
Latest news on medicinal product SPCs in Europe (Article) 1 18
Unified Patent Court
UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

PHARMACEUTICAL PRODUCTS

Antibiotics
Antimicrobial resistance: a brief review of the O’Neill report
(Case Comment) 4 162
UN leads the way on antimicrobial resistance
(Case Comment) 6 252

Clinical trials
Regulatory guidance: the importance of clarity
R (Richmond Pharmacology Ltd) v Health Research Authority (Case Comment) 4 158

Competition
GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements (Case Comment) 2 68

Injunctions
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111

PLANT BREEDING

Royalties
Generating value in the soybean chain through royalty collection: an international study (Article) 5 171

TRADE SECRETS
EU Trade Secrets Directive: a case of form over substance (Article) 6 239

Countries and Institutions

ARGENTINA
Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 176

AUSTRALIA
Data exclusivity
Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia (Case Comment) 2 73

Patents
Isolated nucleic acid sequences no longer patentable in Australia:
D’Arcy v Myriad Genetics Inc (Case Comment) 1 25
Patentability of medical treatments (Article) 6 224

BELGIUM
Medicinal products
Promoting the off-label use of medicines: where to draw the line? (Article) 1 3

BRAZIL
Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 179

CANADA
Patents
Diagnostic method claims in Canada (Article) 1 12

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 182

COURT OF JUSTICE OF THE EUROPEAN UNION

Patents
Calculation of SPC duration: Case C–471/14 Seattle Genetics (Case Comment) 1 31
Genentech: the Court of Justice of the EU rejects a competition law defence in a patent royalty action (Case Comment) 4 165
Latest case on SPCs: the CJEU rules in favour of chaos (Case Comment) 6 248

EUROPEAN COMMISSION

Patents
EU Commission notice on plants from essentially biological processes: problem solved? (Article) 6 231

EUROPEAN UNION

Cosmetic products
Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by Sophora Japonica (Article) 4 142

Medicinal products
Promoting the off-label use of medicines: where to draw the line? (Article) 1 3

Nagoya Protocol
EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources (Article) 3 83
Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by Sophora Japonica (Article) 4 142

Nanomaterials
Nanomaterials in the EU regulatory framework on chemical products (Article) 2 49

Patents
Experts in the Unified Patent Court (Article) 2 44
Latest news on medicinal product SPCs in Europe (Article) 1 18
UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

Trade secrets
EU Trade Secrets Directive: a case of form over substance (Article) 6 239

FRANCE

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 184

GERMANY

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 187

HUNGARY

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 189

INDIA

Patents
Compulsory licences and patent revocations: does public interest rule the roost? (Article) 4 148
ITALY

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 192

PARAGUAY

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 195

SERBIA

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 197

SOUTH AFRICA

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 199

UNIFIED PATENT COURT

Experts in the Unified Patent Court (Article) 2 44
UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

UNITED KINGDOM

Competition
GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements (Case Comment) 2 68
GM insects
What’s all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects (Case Comment) 2 76
International relations
Brexit and life sciences: product authorisation and exclusivity rights (Article) 6 215
Medicinal products
Nexus between inspection and enforcement:
R (Roche Registration Ltd) v Secretary of State for Health (Case Comment) 2 63
Patents
Blurred lines? Patents and plausibility (Article) 2 39
Declaratory relief in the English Patents Court (Case Comment) 3 123
Henry Carr J jabs patentability in Men B case (Article) 4 131
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Patentability of medical treatments (Article) 6 224
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119
Pharmaceutical products
Antimicrobial resistance: a brief review of the O’Neill report (Article) 4 162
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119
Regulatory guidance: the importance of clarity
R (Richmond Pharmacology Ltd) v Health Research Authority (Case Comment) 4 158

UNITED NATIONS

Pharmaceutical products
UN leads the way on antimicrobial resistance (Case Comment) 6 252

UNITED STATES

Patents
Patentability of medical treatments (Article) 6 224
Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 203

URUGUAY

Plant breeding
Generating value in the soybean chain through royalty collection: an international study (Article) 5 204

Contributors
Bateskić-Tubić, Svetlana (Article) 5 197
Belzer, Bill (Article) 5 203
Bergadá, Pablo (Article) 5 176
Blakeney, Michael (Article) 6 224
Broderick, Devra (Case Comment) 2 68
Carter, Ailsa (Article) 4 131
Churi, Asawari (Case Comments) 4 162, 6 252
De Jong, Philipp (Article) 3 83
De la Soujolj, Antoine Alègre (Article) 5 184
De Pastors, Alice (Article) 5 18
Devitt, Crosby (Article) 5 182
England, Paul (Articles) 1 8, 2 44, 6 215; (Case Comment) 3 123
Enriquez, Roberto (Article) 5 176
Forwood, Genevra (Article) 1 3
Gerard, Bryan (Article) 5 203
Goldschagg, Eddie (Article) 5 199
Hull, John (Article) 6 239
Ing, Y. Lynn (Article) 1 12
Jackson, Stuart (Case Comment) 3 119
Killick, James (Article) 1 3; (Case Comment) 1 25
Kock, Michael A. (Article) 6 231
Mendizabal Frers, Juan F. (Article) 5 176
Morgan, Gareth (Case Comment) 1 31
Muyldermans, Dominic (Article) 3 83
Neuman, Teresa (Article) 5 182
Nickless, David (Article) 2 39
O’Connell, Kim (Case Comments) 1 25, 2 73
O’Sullivan, Nina (Article) 3 111
Ojeda G., Maria Estela (Article) 5 195
Payne, Andrew (Case Comment) 3 123
Polgár, Gábor (Article) 5 189
Ramanujan, Adarsh (Article) 4 148
Ramirez de la Piscina, Aratz (Article) 2 49
Rapela, Miguel A. (Article) 5 171, 176
Risso, Diego (Article) 5 204
Roberts, Tim (Book Review) 1 33
Rouguies, José Américo Pierre (Article) 5 179
Rose, David (Article) 3 111
Royle, Matthew (Article) 6 215
Snodin, Mike (Case Comment) 6 248
Spies, Anna (Case Comment) 2 73
Van Vooren, Bart (Article) 4 142
Warburton, Chris (Case Comments) 2 63, 4 158
Whitehead, Brian (Case Comment) 3 119
Contributions

ARTICLES

Blurred lines? Patents and plausibility David Nickless 2 39
Brexit and life sciences: product authorisation and exclusivity rights Paul England and Matthew Royle 6 215
Compulsory licences and patent revocations: does public interest rule the roost? Adarsh Ramanujan 4 148
Diagnostic method claims in Canada Y. Lynn Ing 1 12
EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources Philippe de Jong and Dominic Muyldermans 3 83
EU Trade Secrets Directive: a case of form over substance Dominic Muyldermans 3 83

Henry Carr jabs patentability in Men B case

Experts in the Unified Patent Court

Declaratory relief in the English Patents Court

Calculation of SPC duration: Case C–471/14

Antimicrobial resistance: a brief review of the O’Neill report

Isolated nucleic acid sequences no longer patentable in Australia: D’Arcy v Myriad Genetics Inc

Kim O’Connell and James Elsmore 1 25

Latest case on SPCs: the CJEU rules in favour of chaos Mike Snodin 6 248

Nexus between inspection and enforcement:

Regeneron Pharmaceuticals v Kymab and Novo Nordisk

Brian Whitehead and Stuart Jackson 3 119

Regulatory guidance: the importance of clarity

R (Richmond Pharmacology Ltd) v Health Research Authority

Chris Warburton 4 158

UN leads the way on antimicrobial resistance

Asawari Churi 6 252

What’s all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects

Helen Cline 2 76

BOOK REVIEW

Intelectual property and genetically modified organisms: a convergence in laws (Charles Lawson and Berris Charnley, eds) Tim Roberts 1 33

Case List


Arrow Generics Limited and Another v Merck & Co, Inc [2007] EWHC 1900 (Pat) 3 127

D’Arcy v Myriad Genetics Inc and Another (Australia) [2015] HCA 35 1 25

F. Hoffmann-La Roche AG v Accord Healthcare OÜ (CJEU) (Case C–572/15) 5 October 2016 6 248

Fujifilm Kyowa Biologics Co., Ltd v Abbvie Biotechnology Ltd 3 123

Genentech Inc v Hoechts GmbH et Sanofi-Aventis Deutschland GmbH (CJEU) (Case C–567/14) ECLI:EU:C:2016:526

GlaxoSmithKline UK Ltd v Wyeth Holdings LLC [2016] EWHC 1045 (Ch) 4 131

Nokia Corporation v InterDigital Technology Corporation [2004] EWHC 2920 (Pat), [2005] EWCA Civ 624 3 126

R (Richmond Pharmacology Ltd) v Health Research Authority [2015] EWHC 2238 (Admin) 4 158

R (Roche Registration Ltd) v Secretary of State for Health [2015] EWCA Civ 1311 2 63

Regeneron Pharma Inc and Bayer Pharma AG v Genentech Inc [2013] EWCA Civ 93 2 39

Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S [2016] EWHC 87 (Pat) 3 119

Seattle Genetics (CJEU) Case C–471/14 6 October 2015 1 31

Isolated nucleic acid sequences no longer patentable in Australia: D’Arcy v Myriad Genetics Inc

Kim O’Connell and James Elsmore 1 25

Latest case on SPCs: the CJEU rules in favour of chaos

Mike Snodin 6 248

Nexus between inspection and enforcement:

Regeneron Pharmaceuticals v Kymab and Novo Nordisk

Brian Whitehead and Stuart Jackson 3 119

Regulatory guidance: the importance of clarity

R (Richmond Pharmacology Ltd) v Health Research Authority

Chris Warburton 4 158

UN leads the way on antimicrobial resistance

Asawari Churi 6 252

What’s all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects

Helen Cline 2 76

BOOK REVIEW

Intelectual property and genetically modified organisms: a convergence in laws (Charles Lawson and Berris Charnley, eds) Tim Roberts 1 33

Case List


Arrow Generics Limited and Another v Merck & Co, Inc [2007] EWHC 1900 (Pat) 3 127

D’Arcy v Myriad Genetics Inc and Another (Australia) [2015] HCA 35 1 25

F. Hoffmann-La Roche AG v Accord Healthcare OÜ (CJEU) (Case C–572/15) 5 October 2016 6 248

Fujifilm Kyowa Biologics Co., Ltd v Abbvie Biotechnology Ltd 3 123

Genentech Inc v Hoechts GmbH et Sanofi-Aventis Deutschland GmbH (CJEU) (Case C–567/14) ECLI:EU:C:2016:526

GlaxoSmithKline UK Ltd v Wyeth Holdings LLC [2016] EWHC 1045 (Ch) 4 131

Nokia Corporation v InterDigital Technology Corporation [2004] EWHC 2920 (Pat), [2005] EWCA Civ 624 3 126

R (Richmond Pharmacology Ltd) v Health Research Authority [2015] EWHC 2238 (Admin) 4 158

R (Roche Registration Ltd) v Secretary of State for Health [2015] EWCA Civ 1311 2 63

Regeneron Pharma Inc and Bayer Pharma AG v Genentech Inc [2013] EWCA Civ 93 2 39

Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S [2016] EWHC 87 (Pat) 3 119

Seattle Genetics (CJEU) Case C–471/14 6 October 2015 1 31